跳至主要内容
临床试验/TCTR20190605003
TCTR20190605003已完成未知

A comparative study of clinical and laboratory characteristics and disease activity of dipeptidyl peptidase 4 (DPP4) inhibitors-induced bullous pemphigoid and classic bullous pemphigoid in type 2 diabetes mellitus patients

/A0 个研究点目标入组 101 人开始时间: 2019年6月5日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
101

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
15 Years 至 100 Years(—)
性别
All

入选标准

  • Patients aged 15 years or older who were diagnosed with DM2 before the onset of BP were recruited. The diagnosis of BP was confirmed in the patients possessing at least 3 out of the 4 following criteria: clinical consistency with BP; subepidermal separation with dermal inflammatory-cell infiltrations in skin histopathology; IgG and/or C3 depositions in linear pattern along the DEJ by direct immunofluorescence (DIF) or linear IgG on the epidermal side of the skin in salt-split indirect immunofluorescence (IIF); the positive results of anti-BP180 IgG and/or anti-BP230 enzyme-linked immunosorbent assays (ELISA) in patient with equivocal DIF and IIF.

排除标准

  • The patients whose diagnoses were not consistent with BP were dismissed. Sixteen patients having BP induced by other drugs apart from DPP4i agents or having incomplete records were excluded. Five patients were excluded due to conflicting relations and the remaining 16 patients were categorized as DPP4i-induced BP cases.

研究者

发起方
/A

相似试验